| scholarly article | Q13442814 |
| P356 | DOI | 10.2147/NDT.S88117 |
| P8608 | Fatcat ID | release_25izxqrs2zd65pke4ocqgzmrne |
| P932 | PMC publication ID | 4610784 |
| P698 | PubMed publication ID | 26508859 |
| P50 | author | Marco A. Riva | Q43160319 |
| P2093 | author name string | Guido Di Sciascio | |
| P2860 | cites work | The dopamine hypothesis of schizophrenia: version III--the final common pathway | Q22242827 |
| The molecular neurobiology of depression | Q24656261 | ||
| Aripiprazole, alcohol and substance abuse: a review | Q26866003 | ||
| Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis | Q28245879 | ||
| Cellular plasticity cascades in the pathophysiology and treatment of bipolar disorder | Q28251880 | ||
| Chronic treatment with aripiprazole induces differential gene expression in the rat frontal cortex | Q28577651 | ||
| Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection | Q30386608 | ||
| Novel antipsychotics: comparison of weight gain liabilities. | Q33867682 | ||
| Review and management of clozapine side effects. | Q33918754 | ||
| H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. | Q33964839 | ||
| Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. | Q33966353 | ||
| Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride | Q34011162 | ||
| Aripiprazole effects on alcohol consumption and subjective reports in a clinical laboratory paradigm--possible influence of self-control | Q34013720 | ||
| Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence | Q34192699 | ||
| Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain | Q34326136 | ||
| Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs | Q34338202 | ||
| Pharmacokinetics of aripiprazole and concomitant lithium and valproate | Q34376865 | ||
| The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania | Q34606256 | ||
| Aripiprazole in schizophrenia and schizoaffective disorder: A review | Q34616681 | ||
| The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives. | Q34620911 | ||
| Does stimulation of 5-HT(1A) receptors improve cognition in schizophrenia? | Q34809553 | ||
| Which comes first: atypical antipsychotic treatment or cardiometabolic risk? | Q34932314 | ||
| Third generation antipsychotic drugs: partial agonism or receptor functional selectivity? | Q35012574 | ||
| Repeated aripiprazole administration attenuates cocaine seeking in a rat model of relapse | Q35062881 | ||
| Half a century of antipsychotics and still a central role for dopamine D2 receptors | Q35595235 | ||
| Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs | Q36096851 | ||
| Medical risk in patients with bipolar disorder and schizophrenia. | Q36590638 | ||
| Treatment of psychosis: 30 years of progress. | Q36687060 | ||
| GPCR functional selectivity has therapeutic impact | Q36880909 | ||
| Reducing the burden of side effects during long-term antipsychotic therapy: the role of "switching" medications. | Q36890574 | ||
| Intramuscular aripiprazole : a review of its use in the management of agitation in schizophrenia and bipolar I disorder | Q37108184 | ||
| Combined antipsychotic treatment involving clozapine and aripiprazole | Q37136830 | ||
| Does the addition of a second antipsychotic drug improve clozapine treatment? | Q37147547 | ||
| Antipsychotic drug action: antagonism, inverse agonism or partial agonism | Q37159949 | ||
| Strategies for dosing and switching antipsychotics for optimal clinical management. | Q37165544 | ||
| Prolactin-related and metabolic adverse effects of atypical antipsychotic agents | Q37165549 | ||
| Akt/GSK3 signaling in the action of psychotropic drugs | Q37301265 | ||
| A UK consensus on the administration of aripiprazole for the treatment of mania | Q37326130 | ||
| The 'atypicality' of antipsychotics: a concept re-examined and re-defined | Q37391972 | ||
| Antipsychotic drug actions on gene modulation and signaling mechanisms | Q37525390 | ||
| Effects of quetiapine on the brain-derived neurotrophic factor expression in the hippocampus and neocortex of rats | Q48530667 | ||
| Aripiprazole altered plasma levels of brain-derived neurotrophic factor and catecholamine metabolites in first-episode untreated Japanese schizophrenia patients | Q48732182 | ||
| Effects of antipsychotic drugs on BDNF, GSK-3β, and β-catenin expression in rats subjected to immobilization stress | Q48916823 | ||
| Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. | Q51740194 | ||
| Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study. | Q55044398 | ||
| Pharmacokinetics of Aripiprazole and Concomitant Carbamazepine | Q56791101 | ||
| Should antipsychotics take pole position in mania treatment? | Q59210058 | ||
| A dopaminergic mechanism in mania | Q67824100 | ||
| The role of endogenous sensitization in the pathophysiology of schizophrenia: implications from recent brain imaging studies | Q73553209 | ||
| Signal transduction pathways modulated by D2-like dopamine receptors | Q73780889 | ||
| Switching antipsychotic medications: not enough, too often, or just right? | Q84887477 | ||
| The second revision of the dopamine theory of schizophrenia: implications for treatment and drug development | Q87015861 | ||
| Neuronal plasticity: a link between stress and mood disorders | Q37525562 | ||
| Aripiprazole for the maintenance treatment of bipolar I disorder: A review | Q37691643 | ||
| Olanzapine/fluoxetine: a review of its use in patients with treatment-resistant major depressive disorder | Q37692390 | ||
| The effectiveness of multi-target agents in schizophrenia and mood disorders: Relevance of receptor signature to clinical action | Q37695716 | ||
| A systematic review of aripiprazole--dose, plasma concentration, receptor occupancy, and response: implications for therapeutic drug monitoring | Q37768256 | ||
| Antistress properties of antidepressant drugs and their clinical implications | Q37884805 | ||
| Long-acting injectable aripiprazole: how might it fit in our tool box? | Q38104208 | ||
| The preclinical profile of lurasidone: clinical relevance for the treatment of schizophrenia. | Q38120295 | ||
| Aripiprazole (ABILIFY MAINTENA®): a review of its use as maintenance treatment for adult patients with schizophrenia | Q38223569 | ||
| "First do no harm." A systematic review of the prevalence and management of antipsychotic adverse effects | Q38291338 | ||
| Switching antipsychotic medication to aripiprazole: position paper by a panel of Italian psychiatrists | Q38352080 | ||
| Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo | Q38394215 | ||
| Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study | Q38469670 | ||
| Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways. | Q39749438 | ||
| Differential effects of aripiprazole and haloperidol on BDNF-mediated signal changes in SH-SY5Y cells | Q39886992 | ||
| The dopamine hypothesis of schizophrenia: current status, future prospects. | Q40863019 | ||
| Chronic treatment with aripiprazole prevents development of dopamine supersensitivity and potentially supersensitivity psychosis | Q41858651 | ||
| Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial | Q42162953 | ||
| The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine | Q42689992 | ||
| Assessment of safety, tolerability and effectiveness of adjunctive aripiprazole to lithium/valproate in bipolar mania: a 46-week, open-label extension following a 6-week double-blind study | Q43080173 | ||
| Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. | Q44142664 | ||
| Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study | Q44159999 | ||
| Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study | Q44228131 | ||
| Modulation of neuronal plasticity following chronic concomitant administration of the novel antipsychotic lurasidone with the mood stabilizer valproic acid | Q44403456 | ||
| Effect of antipsychotic drugs on brain-derived neurotrophic factor expression under reduced N-methyl-D-aspartate receptor activity | Q44442303 | ||
| A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania | Q44565868 | ||
| Electrophysiological studies in the rat brain on the basis for aripiprazole augmentation of antidepressants in major depressive disorder. | Q45916254 | ||
| Repeated aripiprazole treatment regulates Bdnf, Arc and Npas4 expression under basal condition as well as after an acute swim stress in the rat brain. | Q45968890 | ||
| The relationship between subjective well-being and dopamine D2 receptors in patients treated with a dopamine partial agonist and full antagonist antipsychotics | Q46051346 | ||
| Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study | Q46225391 | ||
| Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors | Q46446352 | ||
| A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine | Q46498360 | ||
| Aripiprazole in the treatment of patients with alcohol dependence: a double-blind, comparison trial vs. naltrexone | Q46565058 | ||
| Effects of novel antipsychotics with mixed D(2) antagonist/5-HT(1A) agonist properties on PCP-induced social interaction deficits in the rat. | Q46594724 | ||
| Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo-controlled study | Q46669710 | ||
| Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial | Q46681464 | ||
| Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models | Q46829192 | ||
| Behavioural and neuroplastic properties of chronic lurasidone treatment in serotonin transporter knockout rats | Q48288448 | ||
| Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens | Q48299770 | ||
| Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study | Q48310435 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacology | Q128406 |
| P304 | page(s) | 2635-2647 | |
| P577 | publication date | 2015-01-01 | |
| P1433 | published in | Neuropsychiatric Disease and Treatment | Q15716332 |
| P1476 | title | Aripiprazole: from pharmacological profile to clinical use | |
| P478 | volume | 11 |
| Q48512330 | Add-on Aripiprazole for Atypical Antipsychotic-induced, Clinically Significant Hyperprolactinemia |
| Q42200936 | Aripiprazole-induced Asymptomatic Hypertension: A Case Report |
| Q42348171 | Aripiprazole-induced Tardive Dyskinesia in 13 Years Old Girl Successfully Treated with Biperiden: A Case Report |
| Q33866125 | Classics in Chemical Neuroscience: Aripiprazole. |
| Q92284878 | Cocaine-Induced Psychosis and Asenapine as Treatment: A Case Study |
| Q57488903 | Comparison of the efficacy and safety of 4 and 2 mg/day brexpiprazole for acute schizophrenia: a meta-analysis of double-blind, randomized placebo-controlled trials |
| Q94464207 | Does DRD2 Taq1A Mediate Aripiprazole-Induced Gambling Disorder? A Pharmacogenetic Hypothesis |
| Q58573463 | Does the Time of Drug Administration Alter the Metabolic Risk of Aripiprazole? |
| Q33662847 | Dose Trends of Aripiprazole from 2004 to 2014 in Psychiatric Inpatients in Korea |
| Q90667291 | Efficacy of Low-Dose Aripiprazole for Treatment of Psychotic Symptoms in a Patient with 22q11.2 Deletion Syndrome |
| Q38851123 | Long-Acting Injectable Antipsychotics in Schizophrenia: Literature Review and Practical Perspective, with a Focus on Aripiprazole Once-Monthly. |
| Q38728328 | Neuroleptic Drugs and PACAP Differentially Affect the mRNA Expression of Genes Encoding PAC1/VPAC Type Receptors |
| Q89566274 | Once-Monthly Long-Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co-occurring Substance Use Disorders: A Multicentre, Observational Study |
| Q47412381 | Palmar hyperhidrosis treated by noninvasive ultrasound stellate ganglion block. |
| Q47549788 | Safety and efficacy of aripiprazole for the treatment of pediatric Tourette syndrome and other chronic tic disorders |
| Q49387505 | Spotlight on once-monthly long-acting injectable aripiprazole and its potential as maintenance treatment for bipolar I disorder in adult patients |
| Q64065144 | Use of atypical antipsychotics and risk of hypertension: A case report and review literature |
Search more.